



Onfi[®] (clobazam) – First-time generic

- On October 23, 2018, [Amneal launched](#) generic versions of Lundbeck's [Onfi \(clobazam\)](#) tablets and oral suspension.
 - In addition, [Breckenridge launched](#) generic versions of Onfi tablets.
 - On October 22, 2018, Hikma/West-Ward, Upsher-Smith, Zydus and Bionpharma received FDA approval of generic Onfi tablets and oral suspension. Launch plans for these products are pending.
 - Onfi is a schedule IV controlled substance.
- Onfi is approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older.
- Onfi carries a boxed warning about risks from concomitant use with opioids.
- According to IQVIA data, U.S sales for Onfi tablets and oral suspension were approximately \$594 million and \$255 million, respectively, for the 12 months ending in August 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.